miR‐33 in cardiometabolic diseases: lessons learned from novel animal models and approaches
Open Access
- 3 May 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in EMBO Molecular Medicine
- Vol. 13 (5), e12606
- https://doi.org/10.15252/emmm.202012606
Abstract
MiRNAs have emerged as critical regulators of nearly all biologic processes and important therapeutic targets for numerous diseases. However, despite the tremendous progress that has been made in this field, many misconceptions remain among much of the broader scientific community about the manner in which miRNAs function. In this review, we focus on miR‐33, one of the most extensively studied miRNAs, as an example, to highlight many of the advances that have been made in the miRNA field and the hurdles that must be cleared to promote the development of miRNA‐based therapies. We discuss how the generation of novel animal models and newly developed experimental techniques helped to elucidate the specialized roles of miR‐33 within different tissues and begin to define the specific mechanisms by which miR‐33 contributes to cardiometabolic diseases including obesity and atherosclerosis. This review will summarize what is known about miR‐33 and highlight common obstacles in the miRNA field and then describe recent advances and approaches that have allowed researchers to provide a more complete picture of the specific functions of this miRNA.Funding Information
- National Heart, Lung, and Blood Institute (R35HL135820, R01HL135012, R01HL105945, K99HL150234)
- National Institute of Diabetes and Digestive and Kidney Diseases (1K01DK120794)
- American Heart Association (16EIA27550005)
This publication has 102 references indexed in Scilit:
- miR‐33 controls the expression of biliary transporters, and mediates statin‐ and diet‐induced hepatotoxicityEMBO Molecular Medicine, 2012
- Insulin Resistance, Hyperglycemia, and AtherosclerosisCell Metabolism, 2011
- Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglyceridesNature, 2011
- miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signalingProceedings of the National Academy of Sciences of the United States of America, 2011
- Cholesterol regulation of receptor‐interacting protein 140 via microRNA‐33 in inflammatory cytokine productionThe FASEB Journal, 2011
- Expression of miR-33 from an SREBP2 Intron Inhibits Cholesterol Export and Fatty Acid Oxidation*Online Journal of Public Health Informatics, 2010
- MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 ( Srebp2 ) regulates HDL in vivoProceedings of the National Academy of Sciences of the United States of America, 2010
- miR-33 links SREBP-2 induction to repression of sterol transportersProceedings of the National Academy of Sciences of the United States of America, 2010
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- The functions of animal microRNAsNature, 2004